Peter B. Jahrling, Ph.D.

Senior Scientist

Emerging Viral Pathogens Section

NIAID/DIR

IRF Building
Room 1A111
8200 Research Plaza
Frederick, MD 21702

301-631-7201

jahrlingp@niaid.nih.gov

Research Topics

The Emerging Viral Pathogens Section (EVPS) conducts basic research to elucidate the pathophysiological processes associated with the severe morbidity caused by infections with viral hemorrhagic fevers and other Category A pathogens. In addition to developing animal models by using authentic microbial agents, EVPS develops treatment strategies that include vaccines, antimicrobials, immunoprophylaxis, and inhibitors of the coagulation cascade and cytokine storm to reverse the consequences of viral infection. Pathogen discovery also is a component of EVPS activities.

Countermeasure development and improved medical outcomes are the objectives of this research initiative. Generic solutions to broad classes of microbial agents should emerge from an understanding of disease processes. Thus, EVPS will assess a broad spectrum of diseases, including newly discovered pathogens, for commonalities amenable to generic intervention strategies.

Biography

Dr. Jahrling received his Ph.D. in medical microbiology from Cornell Medical College. Upon graduation, he served as an Army officer at the U.S. Army Medical Research Institute of Infectious Diseases, where he specialized in viral hemorrhagic fevers requiring biosafety level (BSL)-4 containment. After fulfillment of his military obligation, Dr. Jahrling converted to civilian status and was eventually appointed scientific advisor for the institute. In 2005, Dr. Jahrling accepted appointments as chief scientist of the NIAID Integrated Research Facility in Frederick, Maryland, and chief of the Emerging Viral Pathogens Section.

Selected Publications

  1. Hensley LE, Mulangu S, Asiedu C, Johnson J, Honko AN, Stanley D, Fabozzi G, Nichol ST, Ksiazek TG, Rollin PE, Wahl-Jensen V, Bailey M, Jahrling PB, Roederer M, Koup RA, Sullivan NJ. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog. 2010;6(5):e1000904.

  2. Johnson RF, Via LE, Kumar MR, Cornish JP, Yellayi S, Huzella L, Postnikova E, Oberlander N, Bartos C, Ork BL, Mazur S, Allan C, Holbrook MR, Solomon J, Johnson JC, Pickel J, Hensley LE, Jahrling PB. Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease. Virology. 2015;485:422-30.

  3. Jahrling PB, Keith L, St Claire M, Johnson RF, Bollinger L, Lackemeyer MG, Hensley LE, Kindrachuk J, Kuhn JH. The NIAID Integrated Research Facility at Frederick, Maryland: a unique international resource to facilitate medical countermeasure development for BSL-4 pathogens. Pathog Dis. 2014;71(2):213-9.

  4. Bohannon JK, Lackemeyer MG, Kuhn JH, Wada J, Bollinger L, Jahrling PB, Johnson RF. Generation and characterization of large-particle aerosols using a center flow tangential aerosol generator with a non-human-primate, head-only aerosol chamber. Inhal Toxicol. 2015;27(5):247-53.


This page was last updated on August 2nd, 2017